Tyrosine kinase inhibitors (TKIs) are the standard of care for patients with metastatic non-small cell lung cancers (NSCLC) harbouring epidermal growth factor receptor mutations (EGFRm). However, role TKIs is not established in management stage III EGFRm disease. We describe real-world practice testing and use NSCLC KINDLE study, a multicentre, multi-country observational non-interventional stu...